☆ 4.8 Article

Dynamics of PD-1 expression are associated with treatment efficacy and prognosis in patients with intermediate/high-risk myelodysplastic syndromes under hypomethylating treatment

FRONTIERS IN IMMUNOLOGY (2022)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Substance Abuse

Smoking-related cancer death among men and women in an ageing society (China 2020-2040): a population-based modelling study

Ning Li et al.

Summary: China is facing a growing epidemic of smoking and accelerated aging population, which have significant implications for the future burden of cancer. Based on predictive models, it is projected that if current smoking trends continue, the smoking-related cancer mortality rate among Chinese men and women aged 35 years and older will increase by 44.0% and 52.8% respectively by 2040. Effective tobacco control measures are urgently needed to prevent further increase in cancer deaths in China.

TOBACCO CONTROL (2023)

添加到收藏夹

Article Hematology

A randomized phase 2 trial of azacitidine with or without durvalumab as first-line therapy for higher-risk myelodysplastic syndromes

Amer M. Zeidan et al.

Summary: This study conducted a randomized phase 2 trial comparing the efficacy of Azacitidine plus Durvalumab with Azacitidine monotherapy in the treatment of higher-risk myelodysplastic syndromes. The results showed that the combination therapy did not significantly improve clinical outcomes and was associated with more toxicities.

BLOOD ADVANCES (2022)

添加到收藏夹

Article Hematology

A randomised phase II study of azacitidine (AZA) alone or with Lenalidomide (LEN), Valproic acid (VPA) or Idarubicin (IDA) in higher-Risk MDS or low blast AML: GFM's pick a winner trial, with the impact of somatic mutations

Lionel Ades et al.

Summary: The combination of AZA with other drugs did not improve the outcome observed in higher-risk MDS patients. There was no significant difference in survival and progression-free survival among the different treatment arms. Some combinations led to increased infection rates and hospitalization due to myelosuppression. Factors associated with better treatment response and survival included certain clinical indicators and gene mutations.

BRITISH JOURNAL OF HAEMATOLOGY (2022)

添加到收藏夹

Article Oncology

Pembrolizumab for myelodysplastic syndromes after failure of hypomethylating agents in the phase 1b KEYNOTE-013 study

Guillermo Garcia-Manero et al.

Summary: The phase 1b study evaluated the safety and efficacy of pembrolizumab in patients with myelodysplastic syndromes (MDS) refractory to a hypomethylating agent (HMA). The results showed that pembrolizumab had manageable safety and some clinical activity in these patients. However, treatment-related adverse events were relatively common and no patients achieved complete or partial response.

LEUKEMIA & LYMPHOMA (2022)

添加到收藏夹

Article Medicine, General & Internal

Demethylation and Up-Regulation of an Oncogene after Hypomethylating Therapy

Yao-Chung Liu et al.

Summary: This study found that hypomethylating agents can induce demethylation and up-regulation of the oncogene SALL4 in certain cases, which is associated with poorer prognosis. The critical CpG island for SALL4 expression was identified in the 5' untranslated region. This discovery highlights the need for further investigation into the mechanisms of oncogene activation after treatment with hypomethylating agents.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

添加到收藏夹

Article Hematology

Phase II study of azacitidine with pembrolizumab in patients with intermediate-1 or higher-risk myelodysplastic syndrome

Kelly S. Chien et al.

Summary: The study showed that PD-1 and PD-L1 expression is upregulated in CD34(+) bone marrow cells of MDS patients and combining azacitidine with pembrolizumab had a significant overall response rate of 76% in previously untreated patients. However, the combination therapy had a lower response rate in patients who had failed HMA treatment. Adverse events, such as pneumonia and arthralgias, were common, but manageable, with corticosteroids required in 43% of cases.

BRITISH JOURNAL OF HAEMATOLOGY (2021)

添加到收藏夹

Review Biochemistry & Molecular Biology

Molecular Targeted Therapy and Immunotherapy for Myelodysplastic Syndrome

Paul Lee et al.

Summary: Myelodysplastic syndrome (MDS) is a hematological disorder characterized by ineffective hematopoiesis and predisposition to acute myeloid leukemia (AML). Standard treatment with hypomethylating agents may lead to drug resistance, so combinatorial therapies with targeted therapy or immunotherapy are being explored to improve outcomes.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)

添加到收藏夹

Article Oncology

PD-1 and TIGIT Are Highly Co-Expressed on CD8+ T Cells in AML Patient Bone Marrow

Ling Xu et al.

Summary: The study comprehensively compared the distribution of PD-1 and TIGIT in PB and BM T cells from AML patients, finding a higher percentage of PD-1 and TIGIT single-positive CD8(+) T cells in elderly patients and a higher frequency of PD-1(+) and TIGIT(+) CD8(+) T cells in the BM compared to PB in both DN and R/R patients. This suggests a greater impairment of T cell function in elderly patients and a more immunosuppressive microenvironment in leukemia BM that may promote disease progression.

FRONTIERS IN ONCOLOGY (2021)

添加到收藏夹

Review Oncology

Hypomethylating agent based combinations in higher risk myelodysplastic syndrome

Namrata S. Chandhok et al.

LEUKEMIA & LYMPHOMA (2020)

添加到收藏夹

Review Hematology

Management of higher risk myelodysplastic syndromes after hypomethylating agents failure: are we about to exit the black hole?

Jan Philipp Bewersdorf et al.

EXPERT REVIEW OF HEMATOLOGY (2020)

添加到收藏夹

Article Cell Biology

Genome-wide methylation sequencing identifies progression-related epigenetic drivers in myelodysplastic syndromes

Jing-dong Zhou et al.

CELL DEATH & DISEASE (2020)

添加到收藏夹

Article Oncology

Biology and prognostic impact of clonal plasmacytoid dendritic cells in chronic myelomonocytic leukemia

Nolwenn Lucas et al.

LEUKEMIA (2019)

添加到收藏夹

Article Hematology

Azacitidine with or without lenalidomide in higher risk myelodysplastic syndrome & low blast acute myeloid leukemia

Melita Kenealy et al.

HAEMATOLOGICA (2019)

添加到收藏夹

Review Hematology

Management of myelodysplastic syndromes after failure of response to hypomethylating agents

Angela Gil-Perez et al.

THERAPEUTIC ADVANCES IN HEMATOLOGY (2019)

添加到收藏夹

Article Oncology

Expression of programmed death ligand-1 and programmed death-1 in samples of invasive ductal carcinoma of the breast and its correlation with prognosis

Tingting Zhou et al.

ANTI-CANCER DRUGS (2018)

添加到收藏夹

Meeting Abstract Hematology

Planned Interim Analysis of a Phase 2 Study Evaluating the Combination of Pracinostat, a Histone Deacetylase Inhibitor (HDACi), and Azacitidine in Patients with High/Very High-Risk Myelodysplastic Syndrome (MDS)

Michael K. Keng et al.

BLOOD (2018)

添加到收藏夹

Letter Hematology

Long-term survival of older patients with MDS treated with HMA therapy without subsequent stem cell transplantation

Amer M. Zeidan et al.

BLOOD (2018)

添加到收藏夹

Review Oncology

Checkpoint inhibitors in hematological malignancies

Chi Young Ok et al.

JOURNAL OF HEMATOLOGY & ONCOLOGY (2017)

添加到收藏夹

Article Oncology

Phase 2, Randomized, Double-Blind Study of Pracinostat in Combination With Azacitidine in Patients With Untreated, Higher-Risk Myelodysplastic Syndromes

Guillermo Garcia-Manero et al.

CANCER (2017)

添加到收藏夹

Article Oncology

Association of PD-1, PD-L1, and CTLA-4 Gene Expression and Clinicopathologic Characteristics in Patients With Non-Small-Cell Lung Cancer

Aranzazu Lafuente-Sanchis et al.

CLINICAL LUNG CANCER (2017)

添加到收藏夹

Article Hematology

Causes of death in 2877 patients with myelodysplastic syndromes

Kathrin Nachtkamp et al.

ANNALS OF HEMATOLOGY (2016)

添加到收藏夹

Review Hematology

The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia

Daniel A. Arber et al.

BLOOD (2016)

添加到收藏夹

Article Oncology

The hENT1 and DCK genes underlie the decitabine response in patients with myelodysplastic syndrome

Ping Wu et al.

LEUKEMIA RESEARCH (2015)

添加到收藏夹

Article Oncology

Hypomethylation and up-regulation of PD-1 in T cells by azacytidine in MDS/AML patients: A rationale for combined targeting of PD-1 and DNA methylation

Andreas D. Orskov et al.

ONCOTARGET (2015)

添加到收藏夹

Article Oncology

Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents

H. Yang et al.

LEUKEMIA (2014)

添加到收藏夹

Review Oncology

Immunomodulatory Drugs: New Options for the Treatment of Myelodysplastic Syndromes

Roberto Castelli et al.

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2013)

添加到收藏夹

Article Oncology

Global H3K4me3 genome mapping reveals alterations of innate immunity signaling and overexpression of JMJD3 in human myelodysplastic syndrome CD34+cells

Y. Wei et al.

LEUKEMIA (2013)

添加到收藏夹

Article Hematology

The use of selective immunosuppressive therapy on myelodysplastic syndromes in targeted populations results in good response rates and avoids treatment-related disease progression

Li Xiao et al.

AMERICAN JOURNAL OF HEMATOLOGY (2012)

添加到收藏夹

Article Hematology

Revised International Prognostic Scoring System for Myelodysplastic Syndromes

Peter L. Greenberg et al.

BLOOD (2012)

添加到收藏夹

Article Oncology

New Comprehensive Cytogenetic Scoring System for Primary Myelodysplastic Syndromes (MDS) and Oligoblastic Acute Myeloid Leukemia After MDS Derived From an International Database Merge

Julie Schanz et al.

JOURNAL OF CLINICAL ONCOLOGY (2012)

添加到收藏夹

Review Oncology

Myelodysplastic syndromes: the role of the immune system in pathogenesis

Erica D. Warlick et al.

LEUKEMIA & LYMPHOMA (2011)

添加到收藏夹

Article Hematology

Interferon-γ and tumor necrosis factor-α induce an immunoinhibitory molecule, B7-H1, via nuclear factor-κB activation in blasts in myelodysplastic syndromes

Asaka Kondo et al.

BLOOD (2010)

添加到收藏夹

Article Hematology

Induction of a CD8+ T-cell response to the MAGE cancer testis antigen by combined treatment with azacitidine and sodium valproate in patients with acute myeloid leukemia and myelodysplasia

Oliver Goodyear et al.

BLOOD (2010)

添加到收藏夹

Article Oncology

Tumor Cell Expression of Programmed Cell Death-1 Ligand 1 Is a Prognostic Factor for Malignant Melanoma

Ryosuke Hino et al.

CANCER (2010)

添加到收藏夹

Article Oncology

The DNA demethylating agent 5-aza-2′-deoxycytidine induces expression of NY-ESO-1 and other cancer/testis antigens in myeloid leukemia cells

Maika Almstedt et al.

LEUKEMIA RESEARCH (2010)

添加到收藏夹

Review Immunology

Myeloid-derived suppressor cells as regulators of the immune system

Dmitry I. Gabrilovich et al.

NATURE REVIEWS IMMUNOLOGY (2009)

添加到收藏夹

Review Immunology

PD-1 and its ligands in tolerance and immunity

Mary E. Keir et al.

ANNUAL REVIEW OF IMMUNOLOGY (2008)

添加到收藏夹

Article Cell & Tissue Engineering

Anti-tumor immunotherapy by blockade of the PD-1/PD-L1 pathway with recombinant human PD-1-IgV

C. Zhang et al.

CYTOTHERAPY (2008)

添加到收藏夹

Article Hematology

CD4+CD25high Foxp3+ regulatory T cells in myelodysplastic syndrome (MDS)

Shahram Y. Kordasti et al.

BLOOD (2007)

添加到收藏夹

Article Hematology

Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia

Bruce D. Cheson et al.

BLOOD (2006)

添加到收藏夹

Article Oncology

Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms

SD Gore et al.

CANCER RESEARCH (2006)

添加到收藏夹

Article Oncology

Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using 'real-time' quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR) - a Europe against cancer program

E Beillard et al.

LEUKEMIA (2003)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.